“Birth control has a TikTok problem.”

June 5, 2024

The stakes are high,” reports Lisa Jarvix in Bloomberg. “The twin forces of birth control-related misinformation, often from women sharing their personal experiences, and disinformation, typically posted by right-wing activists hiding their true agendas, is happening at a time of ever-shrinking access to abortion care in the US.”

Your clients have always turned to opinions from family members or friends. But the internet influencers “aren’t typically the ones who are happy with their birth control,” says Jarvix. “It’s the ones who have had a bad experience that are more apt to share.”

Providers can share evidence to counteract the misinformation and disinformation. Here’s an update on the most worrisome risks that contraceptive users care about, according to Contraceptive Technology authors Sarah Bradley, Chelsea Polis, Elizabeth Micks, and Markus Steiner.(2)

Safety

In general, contraceptives pose few serious health risks to the majority of users. Moreover, the use of contraceptive methods, including hormonal methods, is generally far safer than pregnancy. This fact may not be well understood: one study found that 75% of women believed COCs were at least as hazardous to a woman’s health as pregnancy.(3) Contraceptive failure (pregnancy) is associated with risk: an individual must assess the likelihood of contraceptive failure and the dangers that a pregnancy would pose. Depending on where a person lives, they may face risks associated with delayed or unsafe abortion, or risks associated with pregnancy continuation and childbirth. These risks are all affected by an individual’s health and sociocultural circumstances. Thus, people in many lower-income countries with higher pregnancy-related mortality rates will experience an even greater relative health advantage in using contraceptive methods. As people age, they are more likely to have health problems that can complicate pregnancy. Nonetheless, use of hormonal or device-based contraceptive methods (IUDs and implants), and permanent contraception, may entail potential risks.

Major Health Risks

Some contraceptive options, such as fertility awareness–based methods, are not associated with any serious health risks (beyond those associated with pregnancy via method failure). When it comes to the most serious outcome of all—death—the absolute level of risk is extraordinarily low for most people, and lower than the risks associated with pregnancy and birth. Other major health risks, such as blood clots, cancer, anaphylactic reactions, or serious infections, are uncommon. People with underlying medical conditions may have greater health risks from contraception, yet also may have greater health risks from pregnancy. The US Medical Eligibility for Contraceptive Use provides information about the safe use of contraception for individuals with selected medical conditions (see https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html

Risk of Death with Combined Oral Contraceptive Use

Studies using data from the 1990s and earlier compared mortality among users and users of COCs. Some early studies found increased mortality risks among older users and smokers, and especially users who were in both groups.(4-6) Many early studies were based on older formulations using far higher doses of hormones (specifically ethinyl estradol) than found in pills used today. More recent large-scale analyses have found no increase in all-cause mortality associated with oral contraceptive use either in the short term or in the long term.(6-9)

Comparing Risks of Contraceptive Use to Risks of Pregnancy

It may be useful to weigh the low risks associated with COCs and permanent contraception against the risks associated with carrying a pregnancy to term and delivery. The risk of death associated with COC use is 0.06 in 100,000 among nonsmoking users aged 15–34, and 3 in 100,000 for those aged 35 to 44; for smokers aged 15–34, the risk is 1.7 in 100,000.(6)  The risk of death among those undergoing fallopian tube surgery for permanent contraception is 1.5 in 100,000.(10) 

The most recent data available, from 2019, show an increasing maternal mortality rate in the United States.(11)  Among all women, there were 20.1 deaths due to maternal causes for every 100,000 live births. Risks are substantially higher for Black women and older women. The maternal mortality rate for non-Hispanic Black women was 44 deaths per 100,000 live births, 2.5 times the rate for non-Hispanic White women (17.9) and 3.5 times the rate for Hispanic women (12.6). Maternal mortality rates also increased with maternal age, from 12.6 for women younger than age 25, to 19.9 for those aged 25–39, and 75.5 for those aged 40 and older. The mortality risk for women aged 40 and older was 6 times higher than the rate for women younger than age 25. 

The risk of death associated with legal abortion is low, approximately 0.6 in 100,000; this varies by gestational age and method (medication or surgical).(12,13)   However, the risks of unsafe abortion are substantially greater. The risk of death is 55 per 100,000 unsafe abortions worldwide, accounting for 70,000 deaths per year.(14)  As access to abortion is restricted, the proportion of individuals seeking unsafe abortion increases.

Cardiovascular Disease

Use of combined hormonal contraceptives (CHCs), including COCs, the patch, and vaginal ring, as well as injectable contraceptives, are associated with an increased risk of arterial and venous thromboembolism (ATE and VTE). The most serious thrombotic events, myocardial infarction (MI) and stroke, are extremely rare and much less common than deep venous thrombosis (DVT). Smoking significantly increases the risk of MI, especially in users older than age 35. However, evidence is mixed regarding an increased risk of MI among CHC users of any age who do not smoke and do not have hypertension or diabetes.(15.16)  The risk of stroke in normotensive nonsmokers younger than age 35 may not be increased by use of CHCs,(4,7) except potentially in those with certain medical conditions such as migraines with aura.(18)  The risk of VTE is increased by certain contraceptive methods (two-to fourfold for DMPA, two-to sixfold for COCs, and higher for patches and vaginal rings),(19,20) but the absolute risk is low, ranging from 2 events per 10,000 woman-years among those aged 15 to 19, to 7 events per 10,000 woman-years among those aged 45 to 49.(21,22)

Cancer

Many clients have concerns about the effect of hormonal contraception on cancer risk. COCs are the best studied, as they were the first hormonal method available in the United States. Given that cancer incidence increases with age, and clients potentially use hormonal contraception for several decades, methods must be available on the market for long periods of time before researchers can identify increases in risk, especially when those increases are small. 

At the population level, the net effect of COC use across all cancers is neutral,(23-26)  and ever-users of COCs have a significantly lower death rate from all cancers than do never-users.(7)  Use of COCs (and presumably the patch and ring as well) protects users against cancers of the endometrium and ovary. Longer duration of use increases that protection. A comprehensive review concluded that use of COCs is associated with an increased risk of cancer of the cervix and liver, an increased risk of breast cancer in young women (equivalent to the risk with pregnancy), and a decreased risk of colorectal cancer.(23)  The risk of death is lower among ever-users of COCs than never-users for colorectal,(7.25) uterine,(7,8) ovarian,(6,7) and lymphatic and hematopoietic(25) cancer. Moreover, COC use has neither a harmful nor a beneficial effect on breast cancer mortality.(6,7,27) 

Fewer studies have evaluated cancer risk among users of progestin-only methods of contraception (including POPs, injectables, implants, and levonorgestrel-releasing IUDs). Use of injectable contraception, and likely other progestin-only methods, substantially reduces the risk of endometrial cancer.(28)  Though some studies have identified an increased risk of breast cancer for some progestin-only methods,(29-33)  a 2016 systematic review concluded that progestin-only methods of contraception do not appear to increase the risk of breast cancer.(34)

References

  1. Jarvis L. Birth control has a TikTok problem. Bloomberg, April 11, 2024. https://www.bloomberg.com/opinion/articles/2024-04-11/tiktok-spreads-birth-control-falsehood-doctors-should-fight-back?embedded-checkout=true&leadSource=uverify wall
  2. Bradley S, Polis C, Micks E, Steiner M. Effectiveness, safety, and comparative side effects. In: Cason P, Cwiak C, Edelman A, et al (Eds.). Contraceptive technology. 22nd edition. Burlington, MA: Jones-Bartlett Learning, 2023.
  3. Nelson AL, Shabaik S, Xandre P, et al. Perceptions of health risks associated with pregnancy compared to oral contraceptive use. Contraception. 2019;100(3):193-5. DOI: 10.1016/j.contraception.2019.04.008. 
  4. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348(9026):505-10. 
  5. Schwingl PJ, Ory HW, Visness CM. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am J Obstet Gynecol. 1999;180(1 Pt 1): 241-9. DOI: 10.1016/s0002-9378(99)70182-1. 
  6. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet. 2003;362(9379):185-91. DOI: 10.1016/S0140-6736(03)13907-4. 
  7. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010;340:c927. DOI: 10.1136/bmj.c927. 
  8. Charlton BM, Rich-Edwards JW, Colditz GA, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ 2014;349:g6356. DOI: 10.1136/bmj.g6356. 
  9. Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women’s lifestyle and health co- hort. BMC Cancer 2019;19(1):807. DOI: 10.1186/s12885-019-5985-6. 
  10. Escobedo LG, Peterson HB, Grubb GS, Franks AL. Case-fatality rates for tubal sterilization in U.S. hospitals, 1979 to 1980. Am J Obstet Gynecol. 1989;160(1):147-50. DOI: 10.1016 /0002-9378(89)90108-7. 
  11. Hoyert D. Maternal mortality rates in the United States, 2019. NCHS Health E-Stats. 2021. DOI: https://doi.org/10.15620/cdc:103855. 
  12. Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol. 2012;119(2 Pt 1):215-9. DOI: 10.1097/AOG.0b013e 31823fe923. 
  13. Zane S, Creanga AA, Berg CJ, et al. Abortion-related mortality in the United States: 1998-2010. Obstet Gynecol. 2015;126(2):258-65. DOI: 10.1097/AOG.0000000000000945. 
  14. Shah I, Ahman E. Unsafe abortion: global and regional incidence, trends, consequences, and challenges. J Obstet Gynaecol Can 2009;31(12):1149-58. 
  15. Lewis MA. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives? Am J Obstet Gynecol. 1998;179(3 Pt 2):S68-77. DOI: 10.1053/ob.1998.v179 .a93122. 
  16. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-66. DOI: 10.1056/NEJMoa1111840. 
  17. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348(9026):498-505. 
  18. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6): 590-604. DOI: 10.1016/j.contraception.2016.05.014. 
  19. James AH. Pregnancy, contraception and venous thromboembolism (deep vein thrombosis and pulmonary embolism). Vasc Med. 2017;22(2):166-9. DOI: 10.1177/1358863X176 90601. 
  20. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678-700. DOI: 10.1016/j.contraception.2016.04.014. 
  21. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. DOI: 10.1136 /bmj.b2890. 
  22. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75(5):328-36. DOI: 10.1016/j.contraception .2006.12.018. 
  23. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4 Suppl):S5-22. DOI: 10.1016/j .ajog.2004.01.061. 
  24. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners’ oral contraception study. BMJ 2007;335(7621):651. DOI: 10.1136/bmj.39289.649410.55. 
  25. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1-9. DOI: 10.1016/j.ajog.2017.02.002. 
  26. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82(3):221-9. DOI: 10.1016/j .contraception.2010.04.006. 
  27. Wingo PA, Austin H, Marchbanks PA, et al. Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol. 2007;110(4):793-800. DOI: 10.1097/01.AOG.0000284446 .22251.6e. 
  28. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 2010;17(4):R263-71. DOI: 10.1677/ERC-10-0076. 
  29. Li CI, Beaber EF, Tang MT, Porter PL,DalingJ R, Malone KE.  Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012;72(8): 2028-35. DOI: 10.1158/0008-5472.CAN-11-4064. 
  30. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9(3):e1001182. DOI: 10.1371/journal.pmed.1001182. 
  31. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014; 124(2 Pt 1):292-9. DOI: 10.1097/AOG.0000000000000356. 
  32. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 2016;55(11):1281-4. DOI: 10.1080/0284186X.2016.1175660. 
  33. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996;41(5 Suppl):419-27. 
  34. Samson M, Porter N, Orekoya O, et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 2016;155(1):3-12. DOI: 10.1007/s10549-015-3663-1. 

 

Other Latebreakers

Jun. 05, 2024

“Birth control has a TikTok problem.”

May. 08, 2024

Implant: Unpredictable Bleeding and Management

Mar. 19, 2024

Weight Changes and hormonal contraceptives

Feb. 16, 2024

What most affects contraceptive continuation?

Jan. 03, 2024

Resuming CT monthly updates! Introducing the new edition of Contraceptive Technology

Dec. 20, 2021

Substance use disorder: contraceptive options counseling

Oct. 15, 2021

What’s New in Contraception?

Sep. 21, 2021

Contraceptive Technology Conference!

Aug. 25, 2021

Biologic sexism of STIs

Jul. 16, 2021

Excess breast cancer deaths after COVID-19

Jul. 04, 2021

Contraception for patients with medical conditions

May. 18, 2021

Pelvic Floor Dysfunction

Mar. 04, 2021

Treating vulvodynia

Feb. 11, 2021

Puzzling Over the Hurt Down-Under

Jan. 06, 2021

Serious Mental Illness and Contraception

Oct. 28, 2020

New 13-Cycle Vaginal Contraceptive System

Oct. 08, 2020

The Future of Family Planning in Post-COVID America

Sep. 09, 2020

New ASCCP Guidelines: Implications for FP

Aug. 02, 2020

On the alert: mood disorders during 2020 stressors

Jun. 25, 2020

Sex in the Time of COVID-19

May. 08, 2020

Challenges old and new during the pandemic

Mar. 31, 2020

Reproductive health in the time of Covid-19

Mar. 09, 2020

Talking about toys

Feb. 10, 2020

Missed Pills: The Problem That Hasn’t Gone Away

Jan. 02, 2020

Find the “yes! . . . and” rather than “no” or “but”

Nov. 01, 2019

Digital Family Planning: the Future is Now

Oct. 08, 2019

Irregular Bleeding Due to Contraceptives

Sep. 06, 2019

When she’s low on libido…

Aug. 06, 2019

Ouch! Best approaches to menstrual pain

Jun. 27, 2019

Contraceptive efficacy: understanding how user and method characteristics play their part

May. 29, 2019

Strategizing treatment for chronic heavy menstrual bleeding

May. 10, 2019

Perimenopause

Mar. 27, 2019

Untangling the literature on obesity and contraception

Feb. 26, 2019

High tech apps for no-tech FABM

Jan. 25, 2019

Menstrual exacerbation of other medical conditions

Jan. 04, 2019

From Princeton University: Thomas James Trussell (1949-2018)

Nov. 30, 2018

The Short and Long of IUD Use Duration

Oct. 30, 2018

Selecting a Method When Guidance Isn’t Clear-cut

Oct. 04, 2018

Healthcare in the Time of Digital Expansion

Aug. 30, 2018

Combined pills’ effect on mood disorders

Aug. 30, 2018

The Scoop on Two New FDA-Approved Contraceptive Methods

Aug. 01, 2018

Pregnancy of unknown location—meeting the challenge

Jul. 03, 2018

Big “yes” (with caveats) to CHCs during perimenopause

Apr. 02, 2018

Abortion in the U.S.: safe, declining, and under threat

Feb. 02, 2018

Hope for ovarian cancer screening test

Jan. 03, 2018

Breast cancer still a small risk with some hormonal contraceptives

Dec. 04, 2017

New treatment modality for BV

Nov. 07, 2017

Record rate of HPV-related throat cancer

Oct. 03, 2017

Viruses in semen potentially transmissible

Sep. 01, 2017

Don’t Abstain from Your Role in Abstinence

Jul. 26, 2017

Teens births declining but geographic ‘hotspots’ defy trend

Jun. 27, 2017

Online Medical Abortion Service Effective and Safe

May. 30, 2017

Do Women Really Need to Wait That Long?

May. 05, 2017

Reassuring news on depression and OC use

Apr. 06, 2017

PMDD: Genetic clues may lead to improved treatment

Mar. 02, 2017

Breast cancer risk when there is a family history

Feb. 03, 2017

Body weight link to breast and endometrial cancers (and 11 others)

Jan. 03, 2017

Family Planning in 2017 and Beyond

Dec. 01, 2016

Make Me Cry: Depression Link (Again)?

Nov. 02, 2016

Managing implant users’ bleeding and spotting

Oct. 13, 2016

Zika: Updated guidance for providers

Sep. 06, 2016

Pharmacist-prescribed contraceptives

Aug. 01, 2016

Hot off the press! 2016 MEC and SPR

Jul. 05, 2016

Zika virus fears prompt increased request for abortion in nations outlawing abortions

Jun. 13, 2016

Opioid use epidemic among reproductive-age women

May. 04, 2016

Good news on the family planning home front!

Apr. 04, 2016

War Against Planned Parenthood Hurts Women

Feb. 16, 2016

Win-win for both treatment and prevention

Feb. 08, 2016

Center of the Storm

Dec. 01, 2015

Ambivalence

Nov. 02, 2015

Menopause, mood, mental acuity, and hormone therapy

Oct. 01, 2015

Emergency contraception for teens

Sep. 03, 2015

Postpartum Contraception: Now, Not Later

Aug. 03, 2015

Reproductive tract infections, sexually transmitted infections, or sexually transmitted diseases: “a rose by any other name…”

Jun. 25, 2015

Are we practicing what we preach?

Jun. 02, 2015

Be alert to VTE in hormonal contraceptive users

May. 04, 2015

LARC among teens increased 15-fold, but not enough

Mar. 30, 2015

Brain cancer and hormonal contraception

Mar. 02, 2015

Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use

Feb. 02, 2015

Alcohol consumption when pregnancy is unwanted or unintended

Jan. 12, 2015

Latest Data on Contraceptive Use in the United States

Dec. 01, 2014

LateBreaker sampler from Contraceptive Technology conference

Nov. 05, 2014

Emergency Contraceptive Pill Efficacy and BMI/Body Weight

Sep. 29, 2014

Handout on Unintended Pregnancy and Contraceptive Choice

Aug. 27, 2014

Ask About Withdrawal (Really!)

Jul. 31, 2014

Rules to Practice By: Safety First and Cleanliness is Close to. . .

Jul. 01, 2014

What’s Vanity Fair Got Against the NuvaRing?

Jun. 02, 2014

Promising New Treatment for Hepatitis C

May. 01, 2014

Numbers matter, so make them simple for patients

Apr. 01, 2014

The Recession’s Effect on Unintended Pregnancies

Mar. 05, 2014

Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative

Feb. 03, 2014

Applying the “New” Cervical Cytology Guidelines in Your Practice

Jan. 02, 2014

Acute Excessive Uterine Bleeding: New Management Strategies

Dec. 03, 2013

Medical indications for IUD use in teens

Oct. 09, 2013

Whatever happened to PID?

Oct. 05, 2013

Update on Emergency Contraception